Repatha vs Leqvio Side Effects: What Women Need to Know Before Choosing

Why This Comparison Matters Differently for Women

Heart disease is the leading cause of death in women, yet cardiometabolic drug trials have consistently enrolled far fewer women than men. FOURIER enrolled roughly 25% women, and the ORION program enrolled approximately 28 to 29% women across ORION-10 and ORION-11. That means much of what clinicians know about side-effect rates in women is extrapolated from male-dominant cohorts, not directly studied.

Estrogen influences LDL receptor expression and hepatic cholesterol metabolism. After menopause, LDL rises sharply as estrogen falls, and cardiovascular risk accelerates. PCSK9 enzyme activity itself appears to vary across the menstrual cycle in premenopausal women, though the clinical relevance of that variation for dosing is not yet established. These are not trivial differences.

This article compares Repatha and Leqvio side by side, names the evidence gaps that affect women specifically, and gives you a concrete framework for discussing this choice with your clinician at each life stage.

How the Two Drugs Work (and Why Mechanism Affects Side Effects)

Both drugs block PCSK9, a protein that degrades LDL receptors in the liver. Fewer receptors mean less LDL clearance. Blocking PCSK9 restores those receptors and drives LDL down dramatically. The difference is how they block it.

Evolocumab (Repatha): Monoclonal Antibody

Evolocumab is a fully human monoclonal antibody. It binds circulating PCSK9 protein directly, neutralizing it before it can destroy LDL receptors. Because it is a large protein, it cannot enter cells. Its side-effect profile is driven largely by immune recognition of an injected biologic and the injection itself.

Inclisiran (Leqvio): Small Interfering RNA

Inclisiran works upstream. It is a small interfering RNA that silences the gene transcript for PCSK9 inside liver cells, preventing the protein from being made in the first place. It is delivered via a subcutaneous injection administered in a clinical setting, not at home. Because it targets intracellular gene expression, its mechanism is fundamentally different, and so is its durability: a single dose suppresses PCSK9 production for roughly six months.

Side-Effect Profiles: Drug by Drug

Evolocumab (Repatha) Side Effects

In FOURIER (NEJM 2017), evolocumab was added to statin therapy in 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD). The overall adverse-event rate was similar between evolocumab and placebo groups. Here is what the trial and post-marketing data show:

Injection-site reactions. The most common complaint. In FOURIER, injection-site reactions occurred in about 2.1% of evolocumab-treated patients versus 1.6% on placebo. Reactions are typically mild: transient redness, bruising, or a small bump. Women with higher subcutaneous fat at the injection site (abdomen, thigh, upper arm) may notice slightly different absorption kinetics, though no sex-specific dosing adjustment is required.

Nasopharyngitis and upper respiratory infections. Reported at ~11% in both the evolocumab and placebo groups in FOURIER, suggesting this is largely background rate rather than a drug effect. No causal signal for serious infections has emerged.

Musculoskeletal symptoms. The statin-background makes attributing myalgia difficult. FOURIER did not show a significant excess of muscle-related adverse events attributable to evolocumab. Some case reports exist of new-onset arthralgia, but rates did not differ statistically from placebo.

Neurocognitive effects. Early post-marketing concern about memory impairment with very low LDL levels has not been confirmed in formal analyses. The EBBINGHAUS cognitive substudy of FOURIER tested 1,974 patients and found no difference in neurocognitive function between evolocumab and placebo after a median 19-month follow-up.

Diabetes risk. Unlike statins, evolocumab does not appear to increase incident diabetes risk. FOURIER data showed no significant difference in new-onset diabetes between arms.

Inclisiran (Leqvio) Side Effects

ORION-10 and ORION-11 (NEJM 2020) enrolled 3,522 patients combined. Inclisiran showed a mean 50% reduction in LDL-C with a twice-yearly dosing schedule (after an initial dose at day 1 and day 90). The safety profile was clean, with one important exception:

Injection-site reactions: the main distinction. Inclisiran's injection-site reaction rate was meaningfully higher than comparator, reported in approximately 5% of inclisiran patients versus <1% in the placebo group across ORION trials. The reactions included pain, redness, and bruising at the injection site, but serious reactions were rare. Because inclisiran is administered by a clinician rather than self-injected, the technique is more consistent, which may limit the worst-case variability seen with at-home injections.

Systemic adverse events. Upper respiratory infections (approximately 8 to 9%), urinary tract infections, and musculoskeletal pain were reported, but rates did not differ significantly from placebo. UTIs were noted slightly more often in the inclisiran group in some analyses, which is relevant for women given baseline higher UTI incidence in females.

Liver enzymes. Mild transient elevations in alanine aminotransferase (ALT) were observed in some ORION participants, though rates of clinically meaningful elevation were low and similar to placebo. Routine liver-function monitoring is not required per current labeling, but women with pre-existing non-alcoholic fatty liver disease (NAFLD), which is common in PCOS and perimenopausal weight gain, should mention this to their prescriber.

No RNA off-target signal identified to date. One theoretical concern with siRNA therapy is off-target gene silencing. Post-marketing surveillance and the ORION program have not surfaced a safety signal from this mechanism, but long-term data beyond five years are still accumulating.

Direct Comparison: Where the Data Is Thin

No randomized head-to-head trial has compared evolocumab and inclisiran directly on side-effect rates. The comparison below is synthesized from trial programs conducted under different conditions, different background therapies, and different patient populations. That limitation matters.

The WomanRx Side-Effect Comparison Framework for PCSK9 Inhibitors in Women

| Feature | Repatha (evolocumab) | Leqvio (inclisiran) | |---|---|---| | Injection-site reaction rate | ~2% (trial); self-injected | ~5% (trial); clinician-injected | | Injection frequency | Every 2 weeks or monthly | Twice yearly (after initiation) | | Administration setting | Home | Clinic or pharmacy | | Systemic immune reactions | Rare; antibodies detected in <1% | Not applicable (siRNA, not protein) | | Neurocognitive concerns | Not confirmed (EBBINGHAUS) | No signal identified | | UTI signal | Not prominent | Small, non-significant trend | | Liver enzyme monitoring required | No | No (but flag pre-existing liver disease) | | Women-specific trial data | ~25% of FOURIER | ~28 to 29% of ORION | | Approved for self-administration | Yes | No | | Off-target RNA silencing concern | Not applicable | Theoretical; no confirmed signal |

How Your Hormonal Status Affects Cardiovascular Risk and Drug Choice

Reproductive Years (Ages 18 to ~40)

Women in their reproductive years rarely meet the threshold for PCSK9 inhibitor therapy unless they have familial hypercholesterolemia (FH) or premature ASCVD. Heterozygous FH affects approximately 1 in 250 people, and women with FH may have cardiovascular events earlier than is often recognized clinically. If you have FH and are in your reproductive years, contraception is a critical conversation (see the pregnancy section below).

Estrogen in the premenopausal state is partially protective against ASCVD, but it does not fully offset the LDL burden of FH.

Perimenopause (Roughly Ages 45 to 55)

LDL cholesterol rises during the menopause transition, beginning in late perimenopause. Data from the SWAN cohort showed that LDL increases by approximately 10 to 15 mg/dL through the final menstrual period and the year after. Women who were previously well-controlled on statin therapy alone may find that LDL climbs above goal during perimenopause, making intensification with a PCSK9 inhibitor appropriate.

For a perimenopausal woman still having periods, the twice-yearly clinic visit required for inclisiran may actually be easier to integrate into her existing well-woman care schedule. For a woman who prefers privacy and independence in her regimen, at-home evolocumab may be more practical.

Post-Menopause

Cardiovascular risk rises substantially after menopause. Post-menopausal women with established ASCVD or high-risk FH are the most likely candidates for PCSK9 inhibitor therapy in this demographic. The FOURIER and ORION trials both enrolled predominantly post-menopausal women within their female cohorts, though subgroup analyses by menopausal status were not a primary endpoint.

Menopausal hormone therapy (MHT) does not appear to meaningfully interact with either drug's mechanism, and no dose adjustments are required for women on MHT.

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

Both evolocumab and inclisiran are contraindicated in pregnancy.

Atherosclerotic cardiovascular disease requiring PCSK9 inhibitor therapy is uncommon in women of reproductive age, but familial hypercholesterolemia is not. Any woman of childbearing potential who is prescribed either drug must use reliable contraception.

Evolocumab in Pregnancy

The FDA label for evolocumab states that animal reproduction studies showed no adverse effects on the fetus, but human pregnancy data are extremely limited. Monoclonal IgG antibodies cross the placenta, particularly in the second and third trimesters. There is no established safe dose in pregnancy. If you discover you are pregnant while taking evolocumab, stop the medication and contact your clinician promptly.

Inclisiran in Pregnancy

Inclisiran is contraindicated in pregnancy per FDA labeling. Animal studies showed embryo-fetal toxicity at clinically relevant exposures. The siRNA mechanism targets hepatic gene expression, and the potential for off-target fetal effects from systemic exposure is not well characterized. Given its twice-yearly dosing, if a woman conceives between doses, inclisiran may still be present systemically. Reliable contraception is required throughout treatment.

Lactation

Neither drug has adequate human lactation data. Evolocumab is a large IgG antibody; IgG antibodies are present in breast milk but are generally poorly absorbed in the infant gut. Inclisiran's transfer into breast milk is unknown. Both manufacturers recommend against use during breastfeeding. The decision to continue either drug while breastfeeding should involve a careful discussion with your prescribing clinician and, where appropriate, a maternal-fetal medicine specialist.

Contraception Guidance

Women of reproductive potential on either drug should use a method with <1% typical-use failure rate, such as a hormonal IUD, progestin implant, combined oral contraceptive, or barrier method used consistently. Inclisiran's six-month duration of action means that a missed period or planned pregnancy requires clinician guidance on timing, since the drug cannot be "stopped" in the same way a daily pill can.

Who This Is Right For (and Who Should Think Carefully)

Women Most Likely to Benefit from a PCSK9 Inhibitor

• Post-menopausal women with established ASCVD and LDL above goal on maximally tolerated statin plus ezetimibe
• Women with heterozygous or homozygous familial hypercholesterolemia at any adult life stage (not pregnant)
• Women with statin intolerance documented after a trial of at least two statins

Repatha (Evolocumab) May Suit You Better If:

• You prefer to manage your own injections at home on your own schedule
• You travel frequently and cannot commit to twice-yearly clinic visits
• You need a drug with a longer track record in a broader population (FOURIER enrolled 27,564 patients)
• Your insurance formulary covers evolocumab preferentially

Leqvio (Inclisiran) May Suit You Better If:

• Adherence to a complex self-injection schedule is a barrier for you
• You already attend a cardiology or primary-care clinic regularly and can incorporate the twice-yearly injection there
• You find at-home injection anxiety-provoking
• Your prescriber has access to a clinic administration program

Situations That Warrant Extra Caution

• Active planning for pregnancy in the next 12 months: discuss stopping either drug and timing with your clinician
• Pre-existing liver disease or NAFLD (particularly common in PCOS): alert your clinician; routine monitoring is not mandated but individualized assessment is reasonable
• Women with poorly controlled autoimmune conditions: evolocumab's monoclonal antibody structure theoretically could interact with immune states, though this has not been systematically studied in women with lupus or rheumatoid arthritis

The Evidence Gap: What We Still Don't Know About Women

Women have been underrepresented in PCSK9 inhibitor trials. This is not a minor caveat. It means:

1. Subgroup analyses by sex in FOURIER showed a non-significant trend toward lower MACE benefit in women compared to men, though confidence intervals were wide. This could reflect true biological difference, the smaller sample size, or both.

2. No published analysis has examined whether menopausal status, exogenous estrogen use, or PCOS modifies the efficacy or side-effect rate of either drug.

3. Injection-site reaction rates in women versus men have not been reported separately in any major PCSK9 inhibitor trial, despite the fact that body composition and subcutaneous fat distribution differ meaningfully by sex and hormonal status.

4. Women with PCOS have higher PCSK9 levels than controls in some studies, which raises the question of whether they might respond differently to PCSK9 inhibition. This is an active area of investigation with no clinical guidance yet.

As NAMS (The Menopause Society) states in its 2022 position statement on cardiovascular disease in menopause: "Women remain underrepresented in cardiovascular clinical trials, and sex-specific analyses are needed to guide treatment decisions." We agree, and we will update this article as new data emerge.

Practical Monitoring and What to Watch For

Regardless of which drug your clinician prescribes, here is what to track:

• LDL-C at 4 to 8 weeks after starting either drug, then every 3 to 12 months depending on your risk level
• Injection-site reactions: photograph and date any significant skin reactions; report redness that spreads, significant swelling, or systemic symptoms (hives, difficulty breathing) immediately
• Muscle symptoms: though the PCSK9 inhibitors themselves are not associated with myopathy, most women on these drugs are also on statins, which are; distinguish carefully
• Menstrual changes: no direct mechanistic link exists, but any new irregular bleeding in a perimenopausal woman on a new medication warrants investigation for other causes
• Liver symptoms: jaundice, right-upper-quadrant pain, or significant fatigue should prompt liver-function testing even without a monitoring mandate